This company seems to have been delisted
Reason: Acquired by Kyowa Kirin
Last recorded trade on: March 20, 2024
Source: https://www.ns-healthcare.com/news/kyowa-kirin-wraps-up-acquisition-of-orchard-therapeutics/
Reason: Acquired by Kyowa Kirin
Last recorded trade on: March 20, 2024
Source: https://www.ns-healthcare.com/news/kyowa-kirin-wraps-up-acquisition-of-orchard-therapeutics/
Orchard Therapeutics
ORTX
$16.70
Share price
0.00%
Change (1 day)
244.33%
Change (1 year)
Revenue for Orchard Therapeutics (ORTX)
Revenue in 2023 (TTM): $21.83 Million USD
According to Orchard Therapeutics
's latest financial reports the company's current revenue (TTM 
) is $21.83 Million USD. In 2022 the company made a revenue of $22.65 Million USD an increase over the revenue in the year 2021 that were of $1.67 Million USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Orchard Therapeutics from 2019 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $21.83 M | -3.6% |
| 2022 | $22.65 M | 1252.54% |
| 2021 | $1.67 M | -35.45% |
| 2020 | $2.59 M | 3.26% |
| 2019 | $2.51 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Novocure
NVCR | $0.62 B | 2,746.79% | Jersey |
 Novavax NVAX | $1.21 B | 5,461.80% | 🇺🇸 USA |
 Organovo ONVO | $0.14 M | -99.34% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | $21.83 M | 0.00% | 🇬🇧 UK |